Sponsors (4)
The bill aims to strengthen U.S. and global pandemic preparedness, speed countermeasure development, and support domestic biotech through clearer agency authority and international collaboration — at the cost of higher federal spending, potential safety/oversight trade-offs, and possible governance or diplomatic frictions.
Hospitals, patients, and U.S. communities will face fewer and smaller outbreaks because improved international collaboration and surveillance aims to detect and contain threats earlier and expand access to pandemic products.
Service members, state and local public health systems, and the broader U.S. population may see stronger preparedness and readiness as funds and programs focus development on priority pathogens (including antimicrobial-resistant threats) and accelerate countermeasure availability.
Small biotech and manufacturing businesses could gain more contract and partnership opportunities as international development and commercialization efforts create demand for U.S. firms and jobs.
Taxpayers may incur significant additional federal costs because expanding international public-health programs and funding commercialization or partnership efforts requires new spending.
Hospitals, patients, and regulators could face safety and oversight risks if accelerated commercial pathways or streamlined approvals reduce regulatory rigor for pandemic products.
Hospitals and state/local health authorities may be excluded from timely response for some emerging threats because narrow statutory definitions could omit pathogens or countermeasures not yet listed by HHS/CDC.
Based on analysis of 4 sections of legislative text.
Requires the State Department, with HHS and others, to produce an international strategy within 18 months to coordinate development, commercialization, equitable access, and stewardship of pandemic countermeasures, including for antimicrobial-resistant pathogens.
Introduced March 9, 2026 by Mike Levin · Last progress March 9, 2026
Requires the State Department, working with HHS and other agencies, to produce and pursue an international strategy within 18 months to get foreign and multilateral partners to help develop, commercialize, deploy, and steward medical countermeasures for pandemics and antimicrobial-resistant pathogens. The strategy must describe how the U.S. will coordinate contributions, strengthen partner countries’ public health capabilities, align with existing U.S. preparedness plans, and consider contracting with U.S. companies and public–private partnerships to promote equitable access and global containment of infectious threats.